Scott Agnew, MD
Family Medicine · Youngstown, OHNPI 1306876628
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 698 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 50 manufacturers, the largest accounting for just 11.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,433 and has fallen 88.1% since, to $290 in 2025. Among family medicine clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 698 payments — averaging $15.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$984
- Amgen$798
- Pfizer$736
- AstraZeneca$720
- Lilly USA, LLC$698
- plus $6K from 44 others
What the payments were for
- Food & beverage$10,93499%
- Education$801%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$11,014 in reported general payments places this provider in the 95th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 156 | $124,332 |
| JardianceEmpagliflozin | 109 | $84,931 |
| OzempicSemaglutide | 73 | $80,728 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 44 | $34,666 |
| KerendiaFinerenone | 24 | $30,377 |
| FarxigaDapagliflozin Propanediol | 20 | $27,808 |
| MounjaroTirzepatide | 20 | $24,463 |
| Breo ElliptaFluticasone/Vilanterol | 53 | $23,895 |
| OxycontinOxycodone Hcl | 15 | $20,780 |
| RexultiBrexpiprazole | 15 | $19,877 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $19,737 |
| TrulicityDulaglutide | 15 | $18,012 |
| EntrestoSacubitril/Valsartan | 23 | $17,102 |
| JanuviaSitagliptin Phosphate | 19 | $12,524 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 16 | $12,374 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $736 | $124,332156 claims |
| Novo NordiskOzempic, Rybelsus, Tresiba | $984 | $96,54098 claims |
| Boehringer IngelheimJardiance | $493 | $84,931109 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $357 | $58,56097 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humulin 70-30 | $698 | $44,45653 claims |
| BayerKerendia | $344 | $30,37724 claims |
| AstraZenecaFarxiga | $720 | $27,80820 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $52 | $19,87715 claims |
| MerckJanuvia, Belsomra | $353 | $17,59330 claims |
| NovartisEntresto | $271 | $17,10223 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $315 | $12,37416 claims |
| Esperion Therapeutics, Inc.Nexletol | $78 | $10,02615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Youngstown
- Kristyn EssadYoungstown$27K
- Russell MorrisonYoungstown$24K
- Joseph GalloYoungstown$21K
- Kwabena OtengSpringdale$2M
- Brian BeesleyColumbus$1.4M
- Darshana PatelBeachwood$648K
- Thomas GraceFindlay$503K
- Susan RatayAshtabula$379K
- Shannon TrotterSpringfield$348K
- Michael HeileCincinnati$272K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.